

Special Issue

Multiple Sclerosis: Diagnosis and Treatment—3rd Edition

Message from the Guest Editor

This Special Issue is the third volume of our previous Special Issue “Multiple Sclerosis: Diagnosis and Treatment”. Multiple Sclerosis (MS), an inflammatory demyelinating disease of the CNS, has acquired worldwide recognition with its increasing global prevalence, including populations previously considered not to be commonly affected. We cordially invite authors and investigators within this complex field of universal interest to submit original research or review articles pertaining to this Special Issue. Studies and opinions on risk factors related to the development of the disease, molecular aspects of its pathogenesis, diagnostic intricacies despite current criteria, and the status of disease-modifying therapies’ effects in the Radiologically Isolated Syndrome (RIS), prodromic, relapsing and progressive forms of MS, and what is foreseen on the horizon are welcome, including management of pediatric demyelinating disease and in the aging individual.

Guest Editor

Prof. Dr. Víctor M. Rivera

Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA

Deadline for manuscript submissions

31 August 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/231042

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).